Weill Cornell Medical College - NY Presbyterian Hospital
Welcome,         Profile    Billing    Logout  
 22 Trials 
46 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Besien, Koen van
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996, Nanatinostat, Valganciclovir
Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
CASE1A17, NCT03143985: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Completed
1
18
US
Vactosertib, TEW-7197, EW7197, EW-7197, Pomalidomide, POM
Koen van Besien
Multiple Myeloma
02/22
09/22
NCT05013437: Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

Withdrawn
1
20
US
Evomela, Melphalan, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine
Koen van Besien
Multiple Myeloma
12/23
03/24
NCT04450069: CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Completed
1
18
US
CLBR001 and SWI019
Calibr, a division of Scripps Research
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma, Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma
05/24
05/24
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
NCT05108623: A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Completed
1
34
US
agenT-797, Approved ICIs
MiNK Therapeutics
Tumor, Solid
01/24
01/24
NCT06698744: UF-KURE-BCMA CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma

Not yet recruiting
1
12
US
UF-KURE-BCMA CAR T-cells, UF-KURE-BCMA cells, Cyclophosphamide, Fludarabine
David Wald
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
12/26
09/28
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Solomon, Scott D
ACTIV-4, NCT04505774 / 2020-004285-19: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Active, not recruiting
4
3239
Europe, US, RoW
theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin
Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI)
Covid19
08/23
06/24
NCT02771197: Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

Completed
2
20
US
Fludarabine, Melphalan, Pembrolizumab
Northside Hospital, Inc., Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
08/22
07/23
NCT04235036: Ibrutinib and Rituxan for Chronic GVHD

Terminated
2
19
US
Rituximab, Ibrutinib
Northside Hospital, Inc., Pharmacyclics LLC.
Graft Vs Host Disease
12/22
12/22
NCT04237623: GM-CSF With Post-Transplant Cyclophosphamide

Recruiting
2
38
US
Sargramostim, GM-CSF, Control Arm, G-CSF
Northside Hospital, Inc.
Transplant-Related Hematologic Malignancy
09/25
09/25
NCT05417971: Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Recruiting
2
20
US
Fludarabine, Total Body Irradiation
Northside Hospital, Inc.
Hematologic Malignancy
07/25
12/25
NCT06337331: Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Withdrawn
2
23
US
Venetoclax, Decitabine, Fludarabine, Busulfan, Total Body Irradiation
Northside Hospital, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
08/26
08/27
NCT05519579: Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia

Recruiting
2
20
US
Methotrexate, Blinatumomab
Northside Hospital, Inc.
Acute Lymphoblastic Leukemia
11/24
08/25
NCT06059391: CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Recruiting
2
216
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Granulocyte Colony-Stimulating Factor, Colony Stimulating Factor 3, Colony-Stimulating Factor (Granulocyte), Colony-Stimulating Factor 3, CSF3, G CSF, G-CSF, GCSF, Granulocyte Colony Stimulating Factor, Pluripoietin, Hematopoietic Cell Transplantation Conditioning Regimen, HCT Conditioning Regimen, HSCT Conditioning Regimen, Stem Cell Transplant Conditioning, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine, Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Pheresis, Apheresed, Apheresis, Blood Component Removal, Collection, Apheresis/Leukapheresis, Hemapheresis, Placebo Administration, Stem Cell Mobilization Therapy, Chemomobilization, Hematopoietic Stem Cell Mobilization, Mobilization Therapy, Stem-cell mobilization
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
01/27
01/28
NCT02828592: Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Recruiting
2
20
US
Fludarabine, Cyclophosphamide, Total Body Irradiation, TBI, Rabbit ATG
Northside Hospital, Inc.
Severe Aplastic Anemia
08/25
08/26
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
NCT06046248: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease

Recruiting
2
25
US
Belumosudil, Rituximab
Northside Hospital, Inc., Sanofi
Chronic Graft Versus Host Disease
12/26
12/27
TAK-007-2001, NCT05020015: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruiting
2
27
US
TAK-007, Chemotherapy Agents
Takeda
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
10/25
06/30
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
RIVER-51, NCT04021368: RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Active, not recruiting
1
112
Europe, US
RVU120(SEL120)
Ryvu Therapeutics SA
Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
12/24
12/24
ORIC-533-01, NCT05227144: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
56
Canada, US
ORIC-533
ORIC Pharmaceuticals
Relapsed or Refractory Multiple Myeloma
09/24
09/24
MT-0169-001, NCT04017130: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

Terminated
1
14
US
MT-0169
Molecular Templates, Inc.
Relapsed and/or Refractory Multiple Myeloma
12/23
12/23
ARDENT, NCT05878184: Study Evaluating SC291 in Subjects With r/r B-cell Malignancies

Active, not recruiting
1
16
US, RoW
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
11/25
11/38
HCHS/SOL, NCT02060344: Hispanic Community Health Study / Study of Latinos

Active, not recruiting
N/A
16400
US
National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Disease
06/24
06/24
NCT06517186: Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction

Recruiting
N/A
180
US
Northwestern University, National Heart, Lung, and Blood Institute (NHLBI), Massachusetts General Hospital, Brigham and Women's Hospital, Mayo Clinic, Wake Forest University Health Sciences, University of Pennsylvania
Heart Failure, Heart Failure With Preserved Ejection Fraction
06/26
06/26
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.

Active, not recruiting
N/A
525
US
Investigational LUX-Dx ICM Implant
Boston Scientific Corporation
Heart Failure
05/26
06/26
NCT05873634: HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets

Recruiting
N/A
1000
US
Northwestern University, National Heart, Lung, and Blood Institute (NHLBI), Massachusetts General Hospital, Brigham and Women's Hospital, Mayo Clinic, University of California, Davis, Wake Forest University Health Sciences, University of Pennsylvania
Heart Failure, Heart Failure With Preserved Ejection Fraction
06/26
06/26
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Curcio, Tania
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
KOMET-001, NCT04067336: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
199
Europe, Canada, US
Ziftomenib
Kura Oncology, Inc.
Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
09/24
09/25
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
ImmunoGen, Inc., Jazz Pharmaceuticals
Acute Myeloid Leukemia
12/24
12/24
AMpLify, NCT06128044: CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
70
US
CB-012, Cyclophosphamide, Fludarabine
Caribou Biosciences, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
11/27
04/28
KOMET-007, NCT05735184: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML

Recruiting
1
212
US
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine
Kura Oncology, Inc.
Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML with Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
05/26
05/27
Chabouni, Fatiha
VERDICT, NCT04259138: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
STOMP-II, NCT04847739: Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas

Active, not recruiting
2
60
US
Seton Placement, AVB-114
Avobis Bio, LLC, Alimentiv Inc.
Perianal Fistula, Crohn's Disease
05/25
08/26
NCT06109441: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Recruiting
2
30
Canada, US
ALTB-268
AltruBio Inc.
Ulcerative Colitis
04/25
03/26
VE202-002, NCT05370885 / 2021-001280-24: VE202 in Patients with Mild-to-Moderate Ulcerative Colitis

Recruiting
2
100
Europe, US, RoW
VE202, Vancomycin Oral Capsule, VE202 Placebo, Vancomycin Placebo
Vedanta Biosciences, Inc.
Ulcerative Colitis, Colitis, Ulcerative
07/25
11/25
MAAIS, NCT01169194: Multi-Center African-American Inflammatory Bowel Disease Study

Recruiting
N/A
2400
US
Johns Hopkins University, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Inflammatory Bowel Disease
08/27
08/27

Download Options